Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those with obesity. The pre-filled, once-weekly pen adds to India’s growing portfolio of GLP-1/GIP and GLP-1 therapies available for home use.
The KwikPen arrives in six dose strengths so clinicians can tailor therapy and step patients up when needed. Lilly has listed the maximum retail prices (MRP) at ₹14,000 for 2.5 mg; ₹17,500 for 5 mg; ₹22,000 for 7.5 mg and 10 mg; and ₹27,500 for 12.5 mg and 15 mg per pen. Because most patients begin at 5 mg, doctors expect many to titrate to higher strengths within a month, depending on response and tolerability.
More choice for patients and doctors
The new pen sits alongside semaglutide (Wegovy), another weekly injectable used for weight management and glycaemic control. Wegovy carries a flat monthly price of ₹17,345 for the 0.25 mg, 0.5 mg, and 1 mg pens (about ₹4,336 per dose). At higher doses, the 1.7 mg strength is ₹24,280 and the 2.4 mg strength is ₹26,015.
Endocrinologists say a broader menu helps individualise care. Dr Rajiv Kovil, senior diabetologist at Zandra Healthcare, noted that physicians will choose products by patient need and drug-specific benefits, including metabolic control, weight effects, and device familiarity. He also pointed out that usable comparisons are limited because head-to-head trials are lacking.
Pens over vials
Lilly expects the pen format to pull demand away from vial presentations, which are typically priced similarly but require separate syringes and carry more steps. For patients who prefer not to inject, oral versions of some incretin therapies still offer an alternative; however, weekly pens remain popular for convenience and adherence.
Pricing outlook
Both Mounjaro and Wegovy are global products; even so, Indian MRPs sit below many overseas list prices. That gap may widen. As semaglutide patents expire in select markets, including India, industry watchers expect price competition to increase in 2026–27. If that happens, physicians anticipate broader access and faster dose optimisation, especially for patients who need higher strengths.
Bottom line: with Mounjaro’s multi-strength http://KwikPenKwikPen now in pharmacies, Indian clinicians and patients gain another mainstream option for weekly incretin therapy. Choice, careful titration, and long-term follow-up will determine outcomes.
